drugset / Trial / NCT04892017
Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a multicenter, open label, first in human (FIH) study of inlexisertib as monotherapy, and in combination with trametinib, binimetinib, or sotorasib in participants with advanced or metastatic solid tumors with RAS/MAPK pathway mutation. The study consists of 2 parts, a dose-escalation phase, and an expansion phase.
Timeline
- Start
- 2021-06-15
- Primary completion
- 2026-03-30
- Completion
- 2026-03-30
Outcome
Outcome not reported
Stopped (Business): “Trial terminated due to business decision, not based on any safety or efficacy concerns.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Binimetinib | Small molecule | — | Oral |
| Subject | Inlexisertib | Small molecule | — | Oral |
| Subject | Sotorasib | Small molecule | — | Oral |
| Subject | Trametinib | Small molecule | — | Oral |